Clinical Trial · NCT05707182

18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study

Overview

The purpose of this study is to investigate the usefulness of PET/MRI with an investigational radioactive drug, 18F-rhPSMA-7.3, and MRI contrast in evaluating patients with prostate cancer eligible for active surveillance. This study is for imaging purposes only and is not a treatment study.

Sponsor

University of Alabama at Birmingham

Phase

Early Phase 1

ClinicalTrials.gov

NCT05707182

Drug / Compound

rhPSMA-7.3

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Men with biopsy-confirmed low risk or favorable intermediate risk prostate cancer who are scheduled to undergo multiparametric prostate MRI and confirmatory biopsy as per institutional active surveillance protocol.

Exclusion

  • Biopsy-proven prostate cancer not eligible for active surveillance per institutional criteria.
  • Current or prior treatment for prostate cancer.
  • Inability to undergo 3 Tesla prostate MRI due to claustrophobia and/or MRI- incompatible devices or MR incompatible metal implants.
  • Suspected prostate cancer without histologic confirmation.